Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric Surgery.

Studied

Retrospective comparison of prior GLP-1 medicine or tirzepatide use versus no prior use before bariatric surgery.

Who / model

11,052 matched adults per group. Prior use meant a prescription 365 to 7 days before surgery; outcomes were tracked from postoperative day 1 through day 90.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Prior use was associated with fewer events in the primary combined cardiovascular outcome (0.3% versus 0.6%) and the key secondary kidney outcome (1.4% versus 2.3%). Coronary events and heart failure were also less frequent.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary